

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Naomi L. Esmon, et al.
Serial No.: 10/088,021
Filed: March 14, 2002
Group: Unassigned
Examiner: Unassigned
For: THROMBOTIC EPISODE RISK ASSAYS USING OXIDIZED
PHOSPHOLIPIDS

Assistant Commissioner For Patents
Box PCT
Washington, D.C. 20231

EXPRESS MAIL NO. EV047873955US

DATE OF DEPOSIT 08 July 2002

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box PCT, Washington, D.C. 20231 on

08 July 2002
(Date of Deposit)

Derrick Gordon
(Name of Depositor)


(Signature)

Date of Signature: 08 July 2002

Dear Sir:

INFORMATION DISCLOSURE STATEMENT


Applicants hereby submit the enclosed Information Disclosure Statement Pursuant to 37 C.F.R. § 1.97(b) or in the alternative, 37 C.F.R. § 1.97(c). If the first Office Action occurs before receipt of this document, pursuant to 37 C.F.R. § 1.97(c) and § 1.17(p), please withdraw the necessary fees from Deposit Account No. 18-1260.

In accordance with the requirements of 37 C.F.R. §§ 1.97 and 1.98, attached please find a Form PTO-1449 listing information for consideration by the Office in connection with its examination of the above-captioned patent application. Copies of each document listed are enclosed herein.

INFORMATION DISCLOSURE STATEMENT
APPLICATION SERIAL NO.: 10/088,021

Applicants submit that no representation is made, and no representation is intended, that more relevant material does not exist, or that the order of presentation of these materials in any way reflects their relative pertinence. The listing on the attached Form PTO-1449 is not intended to constitute an admission of any kind. Specifically, this presentation is not an admission that any of the items listed are properly citable against the above-identified application as prior art.

Respectfully submitted,

By: 
Karen L. Knezek
Registration No. 39,253

KLK/eph/ld

July 8, 2002

SIDLEY & AUSTIN

717 N. Harwood, Suite 3400

Dallas, Texas 75201

(214) 981-3300

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE LIST

(Use several sheets if necessary)

ATT. DOCKET NO.

11146/10904

SERIAL NO.

10/088,021

APPLICANT

ESMON, Naomi L., et al.

FILING DATE

03/14/2002

GROUP

unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5	4	7	2	8	5	2	12/05/95	Smirnov, et al.	C12Q	1/56	09/15/93
	AB												
	AC												
	AD												
	AE												
	AF												
	AG												
	AH												
	AI												
	AJ												
	AK												

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	AL													
	AM													
	AN													
	AO													
	AP													

(Including Author, Title, Date, Pertinent Pages, Etc.).

AR		Aviram, et al., 1991. "Oxidized low-density lipoprotein reduces plasma coagulation in-vitro,"
	✓	<i>Scand J Lab Invest</i> 51:17-21
AS		Barrowcliffe, et al. 1981. "Studies of phospholipid reagents used in coagulation I: general properties and their sensitivity to Factor VIII," <i>Thromb Haemostas</i> 46:629-633 ✓
AT		Barrowcliffe, et al. 1981. "Phospholipid reagents used in coagulation II: factors influencing their sensitivity to heparin," <i>Thromb Haemostas</i> 46:634-637

MINER

DATE CONSIDERED

MINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE LIST (Use several sheets if necessary)	ATT. DOCKET NO.	SERIAL NO.
	11146/10904	10/088,021
	APPLICANT	
	ESMON, Naomi, L., et al.	
	FILING DATE	GROUP
	03/14/2002	unassigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	BL							
	BM							
	BN							
	BO							
	BP							

(Including Author, Title, Date, Pertinent Pages, Etc.).

BR		Billy, et al. 1995. "Prothrombin contributes to the assembly of the factor Va-factor Xa complex at
	✓	phosphatidylserine-containing phospholipid membranes," <i>J Biol Chem</i> 270:26883-26889
BS		Esmon, C.T. and Schwarz, H.P. 1995. "An update on clinical and basic aspects of the protein C anticoagulant
	✓	pathway," <i>Trends Cardiovasc Med</i> 5:141-148
BT		Esmon, et al. 2000. "Antiphospholipid antibodies and the protein C pathway,"
	✓	<i>J Autoimmunity</i> 15:221-225

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE LIST

(Use several sheets if necessary)

ATT. DOCKET NO.

11146/10904

APPLICANT

ESMON, Naomi, L., et al.

FILING DATE

03/14/2002

SERIAL NO.

10/088,021

GROUP

unassigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	CA						
	CB						
	CC						
	CD						
	CE						
	CF						
	CG						
	CH						
	CI						
	CJ						
	CK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	CL							
	CM							
	CN							
	CO							
	CP							

(Including Author, Title, Date, Pertinent Pages, Etc.).

CR		Furie, B. and Furie, B.C. 1988. "The molecular basis of blood coagulation,"
	✓	Cell 53:505-518
CS		Gilbert, G.E. and Arena, A.A. 1995. "Phosphatidylethanolamine induces high affinity binding sites for factor VIII
	✓	on membranes containing phosphatidyl-L-serine," J Biol Chem 270:18500-18505
CT		Horkko, et al. 1996. "Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids,"
	✓	J Clin Invest 98:815-825

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE LIST (Use several sheets if necessary)	ATT. DOCKET NO.	SERIAL NO.
	11146/10904	10/088,021
	APPLICANT	
	ESMON, Naomi, L., et al.	
	FILING DATE	GROUP
	03/14/2002	unassigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
DA						
DB						
DC						
DD						
DE						
DF						
DG						
DH						
DI						
DJ						
DK						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
DL							
DM							
DN							
DO							
DP							

(Including Author, Title, Date, Pertinent Pages, Etc.).

DR	Jain, S.K. 1985. "In vivo externalization of phosphatidylserine and phosphatidylethanolamine in the membrane bilayer and hypercoagulability by the lipid peroxidation of erythrocytes in rats," <i>J Clin Invest</i> 76:281-286
DS	Lesnik, et al. 1995. "Tissue factor pathway inhibitor activity associated with LDL is inactivated by cell- and copper-mediated oxidation," <i>Arteriosclerosis, Thrombosis and Vascular Biology</i> 15:1121-1130
DT	Malech, H.L. and Gallin, J.I. 1987. "Neutrophils in human diseases," <i>N Engl J Med</i> 317:687-694

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE LIST (Use several sheets if necessary)	ATT. DOCKET NO.	SERIAL NO.
	11146/10904	10/088,021
	APPLICANT	
	ESMON, Namoi, L., et al.	
	FILING DATE	GROUP
	03/14/2002	unassigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
EA							
EB							
EC							
ED							
EE							
EF							
EG							
EH							
EI							
EJ							
EK							

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
EL								
EM								
EN								
EO								
EP								

(Including Author, Title, Date, Pertinent Pages, Etc.).

ER		Mann, et al. 1988. "Cofactor proteins in the assembly and expression of blood clotting enzyme complexes,"
	✓	<i>Ann Rev Biochem</i> 57:915-956
ES	✓	McCord, J.M. 1985. "Oxygen-derived free radicals in postischemic tissue injury,"
	✓	<i>N Engl J Med</i> 312:159-163
ET		Neuenschwander, et al. 1995. "Phosphatidylethanolamine augments factor VIIa-tissue factor activity: enhance
	✓	ment of sensitivity to phosphatidylserine," <i>Biochemistry</i> 34:13988-13993

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE LIST (Use several sheets if necessary)		ATT. DOCKET NO.		SERIAL NO.	
		11146/10904		10/088,021	
		APPLICANT			
		ESMON, Naomi, L., et al.			
		FILING DATE		GROUP	
		03/14/2002		unassigned	

U.S. PATENT DOCUMENTS												
*EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	FA											
	FB											
	FC											
	FD											
	FE											
	FF											
	FG											
	FH											
	FI											
	FJ											
	FK											

FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
												YES	NO	
	FL													
	FM													
	FN													
	FO													
	FP													

(Including Author, Title, Date, Pertinent Pages, Etc.).		
	FR	Pei, et al. 1993. "Specific contribution of different phospholipid surfaces to the activation of prothrombin by the
		✓ fully assembled prothrombinase," <i>J Biol Chem</i> 268:3226-3233
	FS	Rauch, et al. 1986. "Human hybridoma lupus anticoagulants distinguish between lamellar and hexagonal phase
		✓ lipid systems," <i>J Biol Chem</i> 261: 9672-9677
	FT	Smeets, et al. 1996. "Contribution of different phospholipid classes to the prothrombin converting capacity of
		sonicated lipid vesicles," <i>Thromb Res</i> 81:419-426

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.	

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE LIST (Use several sheets if necessary)	ATT. DOCKET NO.	SERIAL NO.
	11146/10904	10/088,021
	APPLICANT	
	ESMON, Naomi, L., et al.	
	FILING DATE	GROUP
	03/14/2002	unassigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	GA						
	GB						
	GC						
	GD						
	GE						
	GF						
	GG						
	GH						
	GI						
	GJ						
	GK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	GL							
	GM							
	GN							
	GO							
	GP							

(Including Author, Title, Date, Pertinent Pages, Etc.).

GR	Smirnov, M.D. and Esmon, C.T. 1994. "Phosphatidylethanolamine incorporation into vesicles selectively enhances
	✓ factor Va inactivation by activated protein," <i>J Biol Chem</i> 269:816-819
GS	Smirnov, et al. 1995. "On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by
	✓ antiphospholipid antibodies," <i>J Clin Invest</i> 94:309-316
GT	Smirnov, et al. 1999. "The effect of membrane composition on the hemostatic balance,"
	✓ <i>Biochem</i> 38:3591-3598

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.